Development and validation of the capacity of daily living during the morning questionnaire and the global chest symptoms questionnaire in COPD

European Respiratory Journal

Volumn 36, Issue 1, 2010, Pages 96-104

  Partridge, M R ^a   Miravitlles, M ^b   Stahl E ^c   Karlsson, N ^c   Svensson, K ^d   Welte, T ^e  

^a CHARING CROSS HOSPITAL   (United Kingdom)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^c ASTRAZENECA R AND D   (Sweden)

^d HEOR Consulting   (Sweden)

^e HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Capacity of daily living during the morning questionnaire; Chronic obstructive pulmonary disease; Global chest symptoms questionnaire; Morning symptoms and activities; Patient reported outcomes

Indexed keywords

BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; FLUTICASONE PROPIONATE PLUS SALMETEROL; PLACEBO; TIOTROPIUM BROMIDE;

ADULT; AGED; ARTICLE; CAPACITY OF DAILY LIVING DURING THE MORNING QUESTIONNAIRE; CHRONIC DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; DAILY LIFE ACTIVITY; DISEASE SEVERITY; FEMALE; FORCED EXPIRATORY VOLUME; GLOBAL CHEST SYMPTOMS QUESTIONNAIRE; HUMAN; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RELIABILITY; SCORING SYSTEM; TREATMENT OUTCOME; VALIDATION STUDY; CONTROLLED STUDY; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PSYCHOLOGY; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY; SEVERITY OF ILLNESS INDEX; VERY ELDERLY;

ACTIVITIES OF DAILY LIVING; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 77954648021     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00123709     Document Type: Article

References (24)

1. Borsboom GJJ, van Pelt W, van Houwelingen HC, et al. Diurnal variation in lung function in subgroups from two Dutch populations. Am J Respir Crit Care Med 1999; 159: 1163-1171.
2. Calverley PM, Lee A, Towse L, et al. Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease. Thorax 2003; 58: 855-860. (Pubitemid 37239232)
3. McCarley C, Hanneman SK, Padhye N, et al. A pilot home study of temporal variations of symptoms in chronic obstructive lung disease. Biol Res Nurs 2007; 9: 8-20.
4. Postma DS, Koeter GH, Mark TW, et al. The effects of oral slow-release terbutaline on the circadian variation in spirometry and arterial blood gas levels in patients with chronic airflow obstruction. Chest 1985; 87: 653-657.
5. Partridge MR, Karlsson N, Small IR. Patient insight into the impact of chronic obstructive pulmonary disease in the morning: an internet survey. Curr Med Res Opin 2009; 25: 2043-2048.
6. Miravitlles M, Llor C, de Castellar R, et al. Validation of the COPD severity score for its use in primary care: the NEREA study. Eur Respir J 2009; 33: 519-527.
7. Curtis JR, Patrick DL. The assessment of health status among patients with COPD. Eur Respir J 2003; 21: Suppl. 41, 36s-45s.
8. Santo Tomas LH, Varkey B. Improving health-related quality of life in chronic obstructive pulmonary disease. Curr Opin Pulm Med 2004; 10: 120-127. (Pubitemid 38402538)
9. Jones PW, Agusti AGN. Outcomes and markers in the assessment of chronic obstructive pulmonary disease. Eur Respir J 2006; 27: 822-832. (Pubitemid 44914209)
10. Miravitlles M, Anzueto A, Legnani D, et al. Patient's perception of exacerbations of COPD - the PERCEIVE study. Respir Med 2007; 101: 453-460.
11. Partridge M, Karlsson N, Ståhl E. Development of the Morning Activities and Symptoms Questionnaire (MASQ) for COPD. Eur Respir J 2008; 32: Suppl. 52, 814s.
12. Welte T, Miravitlles M, Hernandez P, et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009; 180: 741-750.
13. Welte T. Optimising treatment for COPD - new strategies for combination therapy. Int J Clin Practice 2009; 63: 1136-1149.
14. Partridge MR, Schuermann W, Beckman O, et al. Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD. Ther Adv Respir Dis 2009; 3: 1-11.
15. Meguro M, Barley EA, Spencer S, et al. Development and validation of an improved, COPD-specific version of the St. George Respiratory Questionnaire. Chest 2007; 132: 456-463.
16. Jones P, Spencer S, Adie S. The St George's Respiratory Questionnaire Manual, Version 2.1. London, St George's Hospital Medical School, 2003.
17. Van der Molen T, Willemse BW, Schokker S, et al. Development, validity and responsiveness of the Clinical COPD Questionnaire. Health Qual Life Outcomes 2003; 1: 13.
18. Revicki D, Hays RD, Cella D, et al. Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol 2008; 61: 102-109.
19. Wyrwich KW, Bullinger M, Aaronson N, et al. Estimating clinically significant differences in quality of life outcomes. Qual Life Res 2005; 14: 285-295.
20. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care 2003; 41: 582-592.
21. Partridge MR, Karlsson N. Patient insights on the impact of morning symptoms of COPD. COPD: J Chron Obstruct Pulmon Dis 2008; 5: 395-401.
22. Pitta F, Takaki MY, Oliviera NH, et al. Relationship between pulmonary function and physical activity in daily life in patients with COPD. Respir Med 2008; 102: 1203-1207.
23. Halpin DM, Peterson S, Larsson TP, et al. Identifying COPD patients at increased risk of mortality: Predictive value of clinical study baseline data. Respir Med 2008; 102: 1615-1624.
24. Cohen J. Statistical Power Analysis for the Behavioural Sciences. Hillsdale, Lawrence Erlbaum Associates, 1988.